soft tissue sarcoma

Type: Keyphrase
Name: soft tissue sarcoma
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Photographer’s charity bid

An amateur photographer from Fenny Compton who survived cancer has created a village calendar to raise funds for Cancer Research UK.Tim Baxter was diagnosed with a soft tissue sarcoma after finding a lump on his leg in June last year. Following a successful ... [Published Banbury Guardian - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Prognostic Factors of Pazopanib in Soft Tissue Sarcomas

Share this article:Flavopiridol + FOLFOX 'Active' Against Some Late-relapse Germ Cell TumorsA new analysis confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated ... [Published Chemotherapy Advisor - Apr 16 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 2 reports

Nanobiotix eyes "pivotal" 2014

(EPA:NANO) is set for a "pivotal" 2014 as it acclerates its product pipeline and seeks partners in international markets, it said, releasing 2013 results.The French R&D firm is using nanotechnology to create a more potent and targeted form of radiotherapy ... [Published Proactive Investors.co.uk - Apr 11 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Organic Food Consumption Does Not Lower Cancer Risk

Women who always or mostly eat organic foods have the same likelihood of developing cancer as women who eat conventionally produced foods, according to a new studyResearchers at Oxford University (United Kingdom) conducted a prospective study among 623,080 ... [Published Hospi Medica - Apr 09 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 6 reports

CytRx Corporation Receives Orphan Medicinal Product Designation From European Commission (EC) For Aldoxorubicin In Soft Tissue Sarcoma

LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission ... [Published BioSpace - Mar 31 2014]
First reported Mar 30 2014 - Updated Mar 30 2014 - 1 reports

Forum Post: when will life insurance pay out

incurable secondary soft tissue sarcoma in my lungs. do i have to be told how long i got and under a year for my life insurance to pay out or is the more than mere posability that i my die within a year gonna make them have to pay out. anyone with dealing ... [Published Macmillan Cancer Support - Mar 30 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Organic food consumption and the incidence of cancer in a large prospective study of women in the United Kingdom

Background: Organically produced foods are less likely than conventionally produced foods to contain pesticide residues. Methods: We examined the hypothesis that eating organic food may reduce the risk of soft tissue sarcoma, breast cancer, non-Hodgkin ... [Published GMO Pundit a.k.a. David Tribe - Mar 28 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

A Phase I Study of Temsirolimus and Bryostatin-1 in Patients With Metastatic Renal Cell Carcinoma and Soft Tissue Sarcoma

Background. Temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR) complex 1, is approved for the treatment of metastatic renal cell carcinoma (RCC). Bryostatin-1 inhibits protein kinase C, a downstream effector of mTOR complex 2. We observed ... [Published The Oncologist - Mar 28 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Forum Post: Re: 28 years old and diagnosed with soft tissue sarcoma (possibly MPNST) yesterday

Soft tissue sarcomasA group for anyone affected by any type of soft tissue sarcoma, including those in the fat, muscle, peripheral nerves, synovial sarcomas and angiosarcomas. This is a place to get together, ask questions, share experiences and support ... [Published Macmillan Cancer Support - Mar 28 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

EORTC study does not support combination chemotherapy for soft tissue sarcoma

Results of intergroup phase III randomized controlled EORTC trial 62012An EORTC study published in The Lancet Oncology does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma, unless the ... [Published News-Medical.Net - Mar 27 2014]
First reported Mar 25 2014 - Updated Mar 26 2014 - 3 reports

Should first-line treatment for advanced or metastatic soft tissue sarcoma be doxorubicin alone or doxorubicin with ifosfamide?

An EORTC study published in The Lancet Oncology does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma, unless the objective is to shrink the tumor.Dr. Ian Judson of the Royal Marsden Hospital ... [Published Brightsurf Science News - Mar 26 2014]
First reported Mar 24 2014 - Updated Mar 25 2014 - 5 reports

CytRx To Start Phase 3 Trial Of Aldoxorubicin Under FDA's SPA

CytRx Corporation (CYTR: Quote), a bio-pharmaceutical company specializing in oncology, Monday said under a Special Protocol Assessment or SPA with the FDA, it has begun a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of its ... [Published RTTNews.com - Mar 24 2014]

Quotes

...This technology, which belongs to and was developed by Ziopharm partner Intrexon, is described on the Ziopharm website as being "the most advanced clinical method for precisely modulating protein production in gene based therapies." While there are likely a couple other companies employing similar technology that may wish to challenge that proclamation, it is clear that this technology...
"2013 was a significant eventful year, including major clinical advances for our pipeline of products, NanoXray" said chief executive Laurent Levy on Friday
" 2013 was a significant eventful year, including major clinical advances for our pipeline of products, NanoXray. The annual results presented today are in line with the development plan and incurred expenditures allowed the delivery of significant milestones in accordance with the commitments made ", said Laurent Levy, CEO."
"This is an encouraging step for our team and our partners and we will continue to develop innovative therapies aimed to improve patient care in the fight against cancer."

More Content

All (108) | News (91) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (0) | Press Releases (4)
sort by: Date | Relevance
Doxorubicin-ifosfamide combo improves progressi... [Published Chemotherapy Advisor - 17 hours ago]
Photographer’s charity bid [Published Banbury Guardian - Apr 16 2014]
Prognostic Factors of Pazopanib in Soft Tissue ... [Published Chemotherapy Advisor - Apr 16 2014]
Nanobiotix Appoints Thierry Otin as Head of Man... [Published BioPortfolio - Apr 15 2014]
Ziopharm: Attempting To Rise Again In A Crowded... [Published Seeking Alpha - Apr 15 2014]
TERT promoter hotspot mutations are recurrent i... [Published 7thSpace - Apr 11 2014]
Nanobiotix eyes "pivotal" 2014 [Published Proactive Investors.co.uk - Apr 11 2014]
NANOBIOTIX : 2013 Annual Results [Published 4 Traders - Apr 11 2014]
CytRx Announces Research and Development Day an... [Published Nasdaq - Apr 10 2014]
Quantitative Proteomic Profiling of Pleomorphi... [Published Journal of Proteome Research - Apr 10 2014]
Admiral Pest Control Owner Looses Arm to Cancer... [Published SBWire - Apr 09 2014]
Organic Food Consumption Does Not Lower Cancer ... [Published Hospi Medica - Apr 09 2014]
New: WINGS FLIGHTS OF HOPE Helping Medical Pati... [Published WKBW News 7 - Apr 05 2014]
Organic food: Pricey, not particularly healthy,... [Published The Register - Apr 04 2014]
Nanobiotix to present NBTXR3 data at ASCO meet [Published Proactiveinvestors United Kingdom RSS feed - Apr 02 2014]
CytRx's sarcoma drug aldoxorubicin obtains orph... [Published Pharmaceutical Technology - Apr 01 2014]
The fight of his life [Published Marlborough Express - Apr 01 2014]
BSD Medical Announces BSD's Hyperthermia System... [Published CNBC - Apr 01 2014]
Votrient's extended licence application ditched [Published Pharmafocus - Apr 01 2014]
GSK halts bid for Votrient maintenance use [Published PMLive - Apr 01 2014]
GSK pulls back Votrient for ovarian cancer [Published Pharma Times - Mar 31 2014]
From Dogs, Answers About Breast Cancer [Published Gnom.es - Mar 31 2014]
CytRx Corporation Receives Orphan Medicinal Pro... [Published BioSpace - Mar 31 2014]
CytRx Receives Orphan Medicinal Product Designa... [Published Investing.com - Mar 31 2014]
CytRx Receives Orphan Medicinal Product Designa... [Published Noodls - Mar 31 2014]
CytRx Receives Orphan Medicinal Product Designa... [Published EON Science - Mar 31 2014]
CytRx Receives Orphan Medicinal Product Designa... [Published Business Wire Science: Science News - Mar 31 2014]
CytRx Receives Orphan Medicinal Product Designa... [Published Business Wire Health News - Mar 31 2014]
Forum Post: when will life insurance pay out [Published Macmillan Cancer Support - Mar 30 2014]
Organic food consumption and the incidence of c... [Published GMO Pundit a.k.a. David Tribe - Mar 28 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
CytRx Receives Orphan Medicinal Product Designa... [Published EON Science - Mar 31 2014]
LOS ANGELES--(EON: Enhanced Online News)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European ...
CytRx Receives Orphan Medicinal Product Designa... [Published Business Wire Science: Science News - Mar 31 2014]
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission ...
CytRx Receives Orphan Medicinal Product Designa... [Published Business Wire Health News - Mar 31 2014]
LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission ...
Organic food consumption and the incidence of c... [Published GMO Pundit a.k.a. David Tribe - Mar 28 2014]
Background: Organically produced foods are less likely than conventionally produced foods to contain pesticide residues. Methods: We examined the hypothesis that eating organic food may reduce the risk of soft tissue sarcoma, breast cancer, non-Hodgkin ...
CytRx Initiates Pivotal Global Phase 3 Clinical... [Published EON Science - Mar 24 2014]
LOS ANGELES--(EON: Enhanced Online News)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy ...
1 2 3

Press Releases

sort by: Date | Relevance
NANOBIOTIX: sees Clinical Advance in Soft Tissu... [Published GlobeNewswire: Acquisitions News - Feb 10 2014]
TRACON Pharmaceuticals Initiates Phase 1b Study... [Published GlobeNewswire: Acquisitions News - Feb 03 2014]
Data Presented For ENMD-2076 In Preclinical Mod... [Published PR Newswire - Oct 21 2013]
Oncos Therapeutics Granted Orphan Drug Designat... [Published PR Newswire - Jul 31 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.